A Single-arm, Open-label Exploratory Clinical Study of IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Latest Information Update: 16 Jan 2026
At a glance
- Drugs Antineoplastics (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 12 Jan 2026 Status changed from not yet recruiting to recruiting.
- 05 Jan 2026 New trial record